Nyumba Iphase ds821a

Iphase ds821a

Kufotokozera kwaifupi:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Kulumikizana tsopano Onjezani kugula

Tsatanetsatane wazogulitsa

Matamba a malonda

Kulemba kwazinthu DS - 8210, lomwe limadziwikanso kuti trastuzumab deruxtecan (t - DXD), ndi antibody - Mankhwala Othandizira a Her2 - Axader Axatt. Imaphatikiza a Her2 - kuwongolera antibody (ofanana ndi trastuzumab) ndi exustumabset) ndi toptuismarati (yofanana ndi porpiisomerarab) ndi pontiotoxic) monga Cytotoxic Phondes. Mankhwalawa amafalitsidwa chemotherarapy mwachindunji kwa maselo a khansa akufotokoza za her2, kukonza bwino pomwe akuchepetsa maselo wamba.

Gawo:
Ochelera
Chinthu ayi.:
015200.01
Kukula kwa unit:
50ul, 2mg / ml
Minofu:
N / A
Mitundu:
N / A
Malo osungirako ndi mayendedwe:
Sitolo pa - 70 ° C. Ounda oundana.